Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting
Åsa K Wallin, Carina Wattmo, Lennart MinthonClinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, SwedenBackground: In the absence of long-term, placebo-controlled studies of cholinesterase inhibitors in Alzheimer's disease (AD...
Guardado en:
Autores principales: | Wallin ÅK, Wattmo C, Minthon L |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d29fe1bc9eab474d9048816361a95a2a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Galantamine versus donepezil in Chinese patients with Alzheimer’s disease: results from a randomized, double-blind study
por: Zhang Z, et al.
Publicado: (2012) -
Long-term effect of galantamine on cognitive function in patients with Alzheimer’s disease versus a simulated disease trajectory: an observational study in the clinical setting
por: Nakagawa R, et al.
Publicado: (2017) -
Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
por: Kano O, et al.
Publicado: (2013) -
Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands
por: Hoogveldt B, et al.
Publicado: (2011) -
Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease [Corrigendum]
por: Hager K, et al.
Publicado: (2014)